CSPC Innovation Pharmaceutical (300765) Q2 2025 earnings summary

Executive summary

• Revenue for H1 2025 reached ¥1.05 billion, up 7.99% year-over-year, but net loss attributable to shareholders was ¥2.75 million, reversing a profit of ¥137 million in H1 2024.

• Biopharmaceutical segment saw rapid commercialization of new products and international licensing deals, while functional foods and raw materials maintained stable sales.

• R&D investment surged 81% year-over-year to ¥455 million, representing 43% of revenue.

Financial highlights

• Operating cash flow improved to -¥152 million from -¥941 million year-over-year.

• Gross margin for main business was 38.5%, down 5.59 percentage points year-over-year.

• Government subsidies contributed ¥67.7 million to non-recurring gains.

• Total assets at June 30, 2025: ¥6.17 billion; equity attributable to shareholders: ¥3.71 billion.

Outlook and guidance

• Management expects continued growth in biopharmaceuticals, driven by new product launches and international expansion.

• Ongoing focus on innovation, cost optimization, and global market penetration.